Drug Profile
Research programme: GPR40 agonists - Bristol-Myers Squibb
Latest Information Update: 13 Nov 2013
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action FFAR1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 07 Nov 2013 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
- 31 Dec 2012 Preclinical trials in Metabolic disorders in USA (unspecified route)